Analyst Reco. BeiGene, Ltd. Hong Kong S.E.

Equities

6160

KYG1146Y1017

Market Closed - Hong Kong S.E. Other stock markets 09:08:06 30/04/2024 BST			5-day change	1st Jan Change
94.6 ^HKD	+0.26%		+18.77%	-14.08%

04-23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
04-23	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene to Award Shares Worth $15 Million to 11 Directors	04-17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	04-11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	04-11	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	03-27	MT
Nomura Adjusts Beigene’s Price Target to HK$150.60 From HK$162.05, Keeps at Buy	02-22	MT
Nomura Adjusts BeiGene Price Target to $268.36 From $253.14, Maintains Buy Rating	11-07	MT
Citigroup Lowers Price Target on BeiGene to $285 From $290, Maintains Buy Rating	26/10/23	MT
Future Rate Hike Fears Bring Hong Kong Stocks to Slump; BeiGene Slips 7%	21/09/23	MT
Citigroup Raises BeiGene Price Target to $290 From $285, Maintains Buy Rating	20/09/23	MT
Macquarie Starts BeiGene at Outperform, $259 Price Target	12/09/23	MT
Morgan Stanley Adjusts BeiGene's Price Target to $319 From $321, Keeps Overweight Rating	29/08/23	MT
Jefferies Starts BeiGene at Buy With $287 Price Target	17/08/23	MT
JPMorgan Chase Adjusts Price Target on BeiGene to $300 From $297, Maintains Overweight Rating	07/08/23	MT
Nomura Adjusts BeiGene Price Target to $253.14 From $309.47, Maintains Buy Rating	20/07/23	MT
Nomura Adjusts BeiGene's Price Target to HK$152.86 From HK$186.87, Keeps at Buy	20/07/23	MT
Citigroup Initiates BeiGene With Buy Rating, $275 Price Target	17/07/23	MT
Bernstein Downgrades BeiGene to Market Perform From Outperform, Cuts Price Target to $196 From $335	30/06/23	MT
Nomura Adjusts BeiGene's Price Target to HK$186.87 From HK$172.81, Keeps at Buy	05/05/23	MT
Nomura Adjusts BeiGene Price Target to $309.47 From $286.19, Maintains Buy Rating	05/05/23	MT
Morgan Stanley Adjusts Price Target on BeiGene to $321 From $325, Maintains Overweight Rating	28/02/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BeiGene, Ltd. Hong Kong S.E.

Equities

6160

KYG1146Y1017

Analyst Reco.

Filters